Evaxion Biotech A/S (EVAX)
$2.76-8.00%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $17M
- Beta
- 0.27
- P/E (TTM)
- -0.45
- Short % float
- 0.99%
- Days to cover
- 1.2
- SI change
- -6.0%
- 1W
- -12.66%
- 1M
- -10.10%
- vs SPY 1W
- -12.52%
- vs SPY 1M
- -12.60%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 9
- VALUE
- 9
- GROWTH
- 41
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-36.8%
REV YoY-
ROE-61.4%
EPS YoY-
ROA-44.6%
GROSS100
OP-116
NET-115
[VALUATION]
P/E TTM-0.45
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.12
P/FCF-
EV/EBITDA-1.06
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E74.55
ALTMAN Z-
CURR RATIO5.06
ND/EBITDA-
BETA0.27
Company news
FAQ
- What is LOPJLB’s current signal on EVAX?
- LOPJLB’s latest quantitative signal on Evaxion Biotech A/S (EVAX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is EVAX in?
- Evaxion Biotech A/S (EVAX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Evaxion Biotech A/S (EVAX) do?
- Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a …